Literature DB >> 19084443

Strabismus surgery for internuclear ophthalmoplegia with exotropia in multiple sclerosis.

Wendy E Adams1, Jacqueline A Leavitt, Jonathan M Holmes.   

Abstract

BACKGROUND: Internuclear ophthalmoplegia (INO) is a disabling condition affecting up to 40% of patients with multiple sclerosis (MS). Management of bilateral internuclear ophthalmoplegia (BINO) with exotropia in MS has been controversial because of the uncertain course of MS. Diplopia associated with INO severely impacts the patient's quality of life and, therefore, treatment should be considered.
METHODS: Three patients (ages 28, 62, and 82 years) who had BINO with exotropia and disabling diplopia secondary to MS underwent bilateral medial rectus resections with either unilateral or bilateral adjustable lateral rectus recession(s). Alignment was measured preoperatively and postoperatively, and symptoms were recorded.
RESULTS: Preoperative exotropia ranged from 40(Delta) to 64(Delta) for distance fixation and from 50(Delta) to 70(Delta) for near fixation. Preoperatively, all patients had diplopia at distance and near fixation. Immediately after surgery, patients were adjusted to 10(Delta) to 18(Delta) ET at distance fixation with the expectation of an exotropic drift. None of the patients had a tropia at distance and near fixation 6 months after surgery, with single vision in primary position and reading. Two patients had a 2-year follow-up examination; 1 required a small amount of base-in prism for comfortable reading.
CONCLUSIONS: Three patients who had BINO with exotropia secondary to MS all benefited from surgery. Surgery should be considered as an option for symptomatic patients who have BINO with exotropia caused by MS.

Entities:  

Mesh:

Year:  2008        PMID: 19084443      PMCID: PMC2679866          DOI: 10.1016/j.jaapos.2008.08.008

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  9 in total

1.  Medial rectus resection(s) with adjustable suture for intermittent exotropia of the convergence insufficiency type.

Authors:  D G Choi; A L Rosenbaum
Journal:  J AAPOS       Date:  2001-02       Impact factor: 1.220

2.  Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients.

Authors:  Jason Noble; Farzin Forooghian; Melanie Sproule; Carol Westall; Paul O'Connor
Journal:  Am J Ophthalmol       Date:  2006-09       Impact factor: 5.258

3.  Surgical treatment of supranuclear and internuclear ocular motility disorders.

Authors:  S A Buckley; J S Elston
Journal:  Eye (Lond)       Date:  1997       Impact factor: 3.775

Review 4.  Ocular manifestations of multiple sclerosis.

Authors:  Ling Chen; Lynn K Gordon
Journal:  Curr Opin Ophthalmol       Date:  2005-10       Impact factor: 3.761

5.  Botulinum toxin treatment of supranuclear ocular motility disorders.

Authors:  N J Newman; S R Lambert
Journal:  Neurology       Date:  1992-07       Impact factor: 9.910

6.  Botulinum toxin in the management of internuclear ophthalmoplegia.

Authors:  Ramesh Murthy; Emma Dawson; Sharmina Khan; Gillian G Adams; John Lee
Journal:  J AAPOS       Date:  2007-05-10       Impact factor: 1.220

7.  [A neuro-ophthalmological analysis in 80 cases of multiple sclerosis].

Authors:  Hiromasa Tsuda; Hiroshi Ishikawa; Hanako Matsunaga; Tomohiko Mizutani
Journal:  Rinsho Shinkeigaku       Date:  2004-08

8.  Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients.

Authors:  I Bolaños; D Lozano; C Cantú
Journal:  Acta Neurol Scand       Date:  2004-09       Impact factor: 3.209

9.  Results of extraocular muscle surgery in WEBINO bilateral internuclear ophthalmoplegia patients.

Authors:  Gill Roper-Hall; Oscar A Cruz; Sophia M Chung
Journal:  J AAPOS       Date:  2008-03-10       Impact factor: 1.220

  9 in total
  2 in total

1.  Transposition surgery for WEBINO.

Authors:  Marjan Sajjadi; Seyed Ali Sonbolestan; Seyed Mohammad Ali Abtahi; Zahra Sadat Abtahi
Journal:  Int Ophthalmol       Date:  2016-04-20       Impact factor: 2.031

2.  [Oculomotor system and multiple sclerosis].

Authors:  A E Höh; C Beisse
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.